Choosing the right software translates directly into better client management, operational efficiency and growth for your spa franchise. Discover which tool is best for your business. The ongoing ...

LBH589 is a novel pan-histone deacetylase (HDAC) inhibitor that has potent antitumor activity in multiple myeloma and other hematological malignancies. However, its impact on the immune system has ...

Bristol-Myers Squibb's HDAC inhibitor Istodax has been on the US market for a decade as a treatment for peripheral T-cell lymphoma (PTCL), but will now be withdrawn from sale after a failed phase ...

KLEF Deemed to be University takes pride in announcing a notable breakthrough in the fight against Glioblastoma Multiforme (GBM), an aggressive and fatal form of brain cancer.

It presents a structure–function analysis of four HDAC classes, the NAD +-independent and NAD +-dependent enzymes, subcellular localization, and substrates for deacetylation. Furthermore ...

HDAC inhibitors are already on the market for cancer and some other indications – including Duchenne muscular dystrophy. However, the development of selective HDAC6 inhibitors for cancer has ...